| LTBI Point prevalence | ||
Total Study population (n = 768) | HHCs (n = 245) | CCs (n = 523) | |
LTBI Point prevalence using TST induration ≥ 10 mm: |
| 461/1000 individuals | 367/1000 individuals |
LTBI Point prevalence using IFN-γ Mean level ≥ 0.35 IU/ml: |
| 440/1000 individuals | 203/1000 individuals |